Effects of TA-270 on lung oxidative stress in patients with COPD

• Research type

  Research Study

• Full title

  An open-label, 28-day multiple dose pilot study to evaluate the effects on lung oxidative stress, safety and pharmacokinetics of TA-270 in patients with chronic obstructive pulmonary disease (COPD)

• IRAS ID

  15456

• Sponsor organisation

  Activus Pharma Co., Ltd.

• Eudract number

  2009-009096-35

• ISRCTN Number

  xx

• Research summary

  To assess the effects of TA-270 on predictive biomarkers of oxidative stress in exhaled breath condensate (EBC) such as 8-isoprostane and hydrogen peroxide (H2O2) after 28 days treatment (Visit 4) as compared with baseline (Visit 2). EBC is essentially moisture from a person's exhaled breath. This will be analysed for 8-isoprostane and H2O2 which are factors which indicate inflammation.

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  09/H0802/14

• Date of REC Opinion

  12 Mar 2009

• REC opinion

  Further Information Favourable Opinion